People · Operator
Named in public records as an officer, director or promoter · active 2012–2012 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aragon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $141.5M | $1.8B | 2012 |
Robert A. Adelman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert A. Adelman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Peter Svennilson | 1 | 4 |
| Peter A. Svennilson | 1 | 2 |
| Richard A. Heyman | 1 | 2 |
| Carl A. Gordon | 1 | 1 |
| Faheem A. Hasnain | 1 | 1 |
| Isan A. Chen | 1 | 1 |
| Leo A. Guthart | 1 | 1 |
| Carol A. Gallagher | 1 | 1 |
| Angie A. You | 1 | 1 |
| Brett A. Zbar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.